Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:APGE NYSE:BHVN NASDAQ:CDTX NASDAQ:SLDB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$36.88-1.0%$37.98$26.20▼$63.50$1.70B1.42720,606 shs474,539 shsBHVNBiohaven$13.94-0.9%$14.63$12.79▼$55.70$1.47B1.021.73 million shs1.88 million shsCDTXCidara Therapeutics$65.62+1.2%$60.91$10.14▼$69.36$1.66B1.29385,617 shs378,631 shsSLDBSolid Biosciences$5.39+1.5%$5.94$2.41▼$8.14$419.72M2.541.82 million shs917,652 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-0.59%+0.38%+1.55%-16.21%-26.37%BHVNBiohaven+0.99%-12.13%+4.98%-8.40%-60.44%CDTXCidara Therapeutics+2.25%-0.09%+4.63%+184.02%+458.26%SLDBSolid Biosciences+1.34%-4.50%-12.09%+17.74%-29.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAPGEApogee Therapeutics$36.88-1.0%$37.98$26.20▼$63.50$1.70B1.42720,606 shs474,539 shsBHVNBiohaven$13.94-0.9%$14.63$12.79▼$55.70$1.47B1.021.73 million shs1.88 million shsCDTXCidara Therapeutics$65.62+1.2%$60.91$10.14▼$69.36$1.66B1.29385,617 shs378,631 shsSLDBSolid Biosciences$5.39+1.5%$5.94$2.41▼$8.14$419.72M2.541.82 million shs917,652 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAPGEApogee Therapeutics-0.59%+0.38%+1.55%-16.21%-26.37%BHVNBiohaven+0.99%-12.13%+4.98%-8.40%-60.44%CDTXCidara Therapeutics+2.25%-0.09%+4.63%+184.02%+458.26%SLDBSolid Biosciences+1.34%-4.50%-12.09%+17.74%-29.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAPGEApogee Therapeutics 2.88Moderate Buy$97.29163.79% UpsideBHVNBiohaven 3.13Buy$55.71299.67% UpsideCDTXCidara Therapeutics 3.11Buy$64.14-2.25% DownsideSLDBSolid Biosciences 3.09Buy$15.00178.29% UpsideCurrent Analyst Ratings BreakdownLatest SLDB, APGE, BHVN, and CDTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025BHVNBiohavenRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeModerate Buy ➝ Strong-Buy9/2/2025BHVNBiohavenRaymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageStrong-Buy$75.008/28/2025APGEApogee TherapeuticsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/28/2025APGEApogee TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$78.00 ➝ $87.008/19/2025BHVNBiohavenBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$59.00 ➝ $60.008/14/2025APGEApogee TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/14/2025SLDBSolid BiosciencesChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$15.008/14/2025SLDBSolid BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$15.00 ➝ $13.008/13/2025SLDBSolid BiosciencesWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$17.00 ➝ $14.008/12/2025BHVNBiohavenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$54.00 ➝ $30.008/12/2025BHVNBiohavenLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$60.00 ➝ $50.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAPGEApogee TherapeuticsN/AN/AN/AN/A$15.92 per shareN/ABHVNBiohavenN/AN/AN/AN/A$4.19 per shareN/ACDTXCidara Therapeutics$1.27M1,310.33N/AN/A$14.92 per share4.40SLDBSolid Biosciences$8.09M51.88N/AN/A$3.43 per share1.57Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAPGEApogee Therapeutics-$182.15M-$4.13N/AN/AN/AN/A-34.65%-32.76%11/11/2025 (Estimated)BHVNBiohaven-$846.42M-$7.66N/AN/AN/AN/A-270.65%-143.70%11/11/2025 (Estimated)CDTXCidara Therapeutics-$169.83M-$11.13N/AN/AN/AN/A-50.81%-42.46%11/6/2025 (Estimated)SLDBSolid Biosciences-$124.70M-$2.80N/AN/AN/AN/A-69.70%-56.74%11/5/2025 (Estimated)Latest SLDB, APGE, BHVN, and CDTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025SLDBSolid Biosciences-$0.51-$0.42+$0.09-$0.42N/AN/A8/11/2025Q2 2025APGEApogee Therapeutics-$1.03-$1.13-$0.10-$1.13N/AN/A8/11/2025Q1 2025BHVNBiohaven-$1.94-$1.94N/A-$1.94$0.41 millionN/A8/7/2025Q2 2025CDTXCidara Therapeutics-$1.87-$1.65+$0.22-$1.65N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAPGEApogee TherapeuticsN/AN/AN/AN/AN/ABHVNBiohavenN/AN/AN/AN/AN/ACDTXCidara TherapeuticsN/AN/AN/AN/AN/ASLDBSolid BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAPGEApogee TherapeuticsN/A16.3616.36BHVNBiohaven1.913.823.82CDTXCidara TherapeuticsN/A16.4516.45SLDBSolid BiosciencesN/A9.349.34Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAPGEApogee Therapeutics79.04%BHVNBiohaven88.78%CDTXCidara Therapeutics35.82%SLDBSolid Biosciences81.46%Insider OwnershipCompanyInsider OwnershipAPGEApogee Therapeutics42.77%BHVNBiohaven16.00%CDTXCidara Therapeutics3.89%SLDBSolid Biosciences1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAPGEApogee Therapeutics9146.11 million26.39 millionOptionableBHVNBiohaven239105.79 million88.86 millionOptionableCDTXCidara Therapeutics9025.36 million24.37 millionNo DataSLDBSolid Biosciences10077.87 million76.39 millionOptionableSLDB, APGE, BHVN, and CDTX HeadlinesRecent News About These CompaniesSolid Biosciences Inc. $SLDB Shares Acquired by Alyeska Investment Group L.P.September 8, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Grows Stock Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comWalleye Capital LLC Has $204,000 Holdings in Solid Biosciences Inc. $SLDBSeptember 7, 2025 | marketbeat.comBrokerages Set Solid Biosciences Inc. (NASDAQ:SLDB) Price Target at $15.00September 7, 2025 | americanbankingnews.comEcoR1 Capital LLC Purchases New Stake in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comJump Financial LLC Acquires New Position in Solid Biosciences Inc. $SLDBSeptember 6, 2025 | marketbeat.comSolid Biosciences Inc. $SLDB is Bain Capital Life Sciences Investors LLC's 7th Largest PositionSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stake in Solid Biosciences Inc. $SLDBSeptember 5, 2025 | marketbeat.comSolid Biosciences Inc. (NASDAQ:SLDB) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRedmile Group LLC Has $7.47 Million Stock Position in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comVestal Point Capital LP Sells 1,096,442 Shares of Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comBirchview Capital LP Makes New Investment in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Invests $6.08 Million in Solid Biosciences Inc. $SLDBSeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Takes Position in Solid Biosciences Inc. $SLDBSeptember 3, 2025 | marketbeat.comSolid Biosciences Inc. (SLDB) Presents At Citi's Biopharma Back To School Conference TranscriptSeptember 2, 2025 | seekingalpha.comApis Capital Advisors LLC Purchases Shares of 110,000 Solid Biosciences Inc. $SLDBSeptember 2, 2025 | marketbeat.comSolid Biosciences to Participate at Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comResolute Capital Asset Partners LLC Makes New $555,000 Investment in Solid Biosciences Inc. $SLDBAugust 25, 2025 | marketbeat.comMonashee Investment Management LLC Grows Position in Solid Biosciences Inc. $SLDBAugust 23, 2025 | marketbeat.comLeerink Partnrs Issues Optimistic Forecast for SLDB EarningsAugust 19, 2025 | marketbeat.comQ1 Earnings Forecast for SLDB Issued By Leerink PartnrsAugust 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSLDB, APGE, BHVN, and CDTX Company DescriptionsApogee Therapeutics NASDAQ:APGE$36.88 -0.39 (-1.05%) Closing price 04:00 PM EasternExtended Trading$36.85 -0.03 (-0.07%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.Biohaven NYSE:BHVN$13.94 -0.13 (-0.92%) Closing price 03:59 PM EasternExtended Trading$13.86 -0.08 (-0.61%) As of 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.Cidara Therapeutics NASDAQ:CDTX$65.62 +0.75 (+1.16%) Closing price 04:00 PM EasternExtended Trading$65.63 +0.01 (+0.02%) As of 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Solid Biosciences NASDAQ:SLDB$5.39 +0.08 (+1.51%) Closing price 04:00 PM EasternExtended Trading$5.40 +0.01 (+0.19%) As of 05:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Why Micron Stock Could Outperform NVIDIA in 2025 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
